Related Experiment Video
Updated: Feb 17, 2026
06:40
An Improved Method for Collection of Cerebrospinal Fluid from Anesthetized Mice
Published on: March 19, 2018
66.8K
Amyloid and Tau Biomarkers in CSF
1Kaj Blennow, MD, Ph.D. Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, The Sahlgrenska Academy at University of Gothenburg, Mölndal Campus, Sahlgrenska University Hospital, SE-431 80 Mölndal, Sweden, Tel: + 46 31 3431791, Fax: + 43 31 3432426,
The Journal of Prevention of Alzheimer'S Disease
|December 14, 2017
Summary
Alzheimer's disease (AD) clinical trials for Aβ-targeting drugs are failing. Cerebrospinal fluid (CSF) biomarkers can improve patient selection and confirm drug effectiveness in AD trials.
Area of Science:
- Neuroscience
- Biomarkers
- Clinical Trials
Background:
- Alzheimer's disease (AD) clinical trials targeting amyloid-beta (Aβ) have a high failure rate.
- Trial failures may stem from patient selection, disease stage, trial duration, and poor translation from animal models.
Purpose of the Study:
- To review the role of cerebrospinal fluid (CSF) biomarkers in enhancing AD clinical trials.
- To explore CSF biomarkers for patient diagnostics, enrichment, and theranostics.
Main Methods:
- Review of current literature on AD biomarkers and clinical trial design.
- Analysis of the utility of CSF biomarkers in diagnostics and theranostics.
Main Results:
- Combined clinical and biomarker criteria are essential for accurate AD diagnosis, reducing misdiagnosis rates.
- Biomarkers are crucial for verifying target engagement and downstream effects of Aβ-targeting drugs in patients.
Conclusions:
- CSF biomarkers can significantly improve AD clinical trial design by enabling precise patient enrichment.
- CSF biomarkers offer theranostic potential, confirming drug target engagement and molecular pathology effects in AD trials.
Keywords:
Alzheimer’s diseaseBiomarkerCerebrospinal fluidClinical trial, DiagnosisMild cognitive impairment (MCI)Phosphorylated tauPlasmaTheragnostictau proteinβ-amyloid (Aβ)More Related Videos
Related Concept Videos
03:03Amyloid Fibrils
12.1K
Amyloid fibrils are aggregates of misfolded proteins. Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils.
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
Amyloid deposits were observed as early as 1639 in the liver and the spleen. In 1854, Rudolph Virchow performed iodine staining,...
12.1K
01:26Alzheimer's Disease: Overview
1.8K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.8K